7354-98-5

Basic information

• Product Name: 4-{[(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino}-N-1,3-thiazol-2-ylbenzenesulfonamide
• CAS NO: 7354-98-5
• Molecular Formula: C₁₆H₁₃N₃O₃S₂
• Molecular Weight: 359.4227
• Mol File: 7354-98-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 579.4°C at 760 mmHg
• Flash Point: 304.2°C
• Density: 1.59g/cm³
• Vapor Pressure: 2.03E-13mmHg at 25°C
• Refractive Index: 1.766
• CAS DataBase Reference: 4-{[(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino}-N-1,3-thiazol-2-ylbenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{[(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino}-N-1,3-thiazol-2-ylbenzenesulfonamide(7354-98-5)
• EPA Substance Registry System: 4-{[(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino}-N-1,3-thiazol-2-ylbenzenesulfonamide(7354-98-5)

Safety Data

• Hazardous Substances Data: 7354-98-5(Hazardous Substances Data)

Upstream product

• 72-14-0 Sulfathiazole 
• 90-02-8 salicylaldehyde 

Downstream Products

• 72369-26-7 N-(2-cyano-ethyl)-4-(2-hydroxy-benzylideneamino)-N-thiazol-2-yl-benzenesulfonamide 
• 107340-06-7 [(CH₃)2SnCl₂(HOC₆H₄CHNC₆H₄SO₂NHCNCHCHS)] 
• 101965-88-2 tetrachlorobis(salicylaldehyde-N'-2-thiazolyl sulphanilamide)germanate 
• 95099-48-2 OC₆H₄OBOC₆H₄CHNC₆H₄SO₂NHC₃H₂NS 
• 107340-02-3 [SnCl₂(HOC₆H₄CHNC₆H₄SO₂NHCNCHCHS)] 
• 302801-59-8 Ni(C₅H₅N)2(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS) 
• 302801-60-1 Cu(C₅H₅N)2(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS)*H₂O 
• 302801-58-7 Co(C₅H₅N)2(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS) 
• 302801-51-0 Cu(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS)(H₂O)2*H₂O 
• 302801-66-7 Cu(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS)(H₂O)2 
• 302801-65-6 Ni(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS)(H₂O)2 
• 302801-64-5 Co(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS)(H₂O)2 
• 302801-71-4 Cu(C₅H₅N)2(OC₆H₄CHNC₆H₄SO₂NC₃H₂NS) 

Relevant articles and documents

Synthesis, characterization and crystal structures of two novel sulfa drug Schiff base ligands derived sulfonamide and molecular docking study

The present paper reports the synthesis of two new sulfa drugs: based Schiff base N-(salicylidene) sulfadiazine = sal-sdzH (1) and N-(salicylidene) sulfathiazole = sal-stzH (2) derived from sulfonamide and substituted salicylaldehyde. These compounds were

Synthesis of Schiff base ligand from N-substituted benzenesulfonamide and its complexes: Spectral, thermal, electrochemical behavior, fluorescence quenching, in vitro-biological and in-vitro cytotoxic studies

Convenient synthesis of new octahedral complexes from 4-amino-N-(1,3-thiazol-2-yl) benzenesulfonamide and 2-hydroxybenzaldehyde with the molecular formula [M(L)2Cl2] (where M = Mn(II), Co(II) and Cu(II) ions) have been described. The

Synthesis, characterization, biological evaluation, and molecular docking approach of nickel (II) complexes containing O, N-donor chelation pattern of sulfonamide-based Schiff bases

A series of Schiff bases (L1–L4) that possess in their structure bioactive sulfonamide group and their nickel (II) complexes have been synthesized. Microanalytical analyses, various spectroscopic methods such as Fourier transform infrared spectroscopy (FT-IR), 1H nuclear magnetic resonance (NMR), 13C NMR, UV–Vis, and MS, are used to explore the nature of bonding and to elucidate the chemical structures. The analytical and magnetic values suggest a range of stoichiometries 1:1, 1:2, and 2:1 (M:L) for the synthesized complexes of almost square planar geometry. The spectral comparative interpretation reveals that L1 and L2 coordinate to the central Ni (II) in tetradentate ONON donor sequence, whereas L3 and L4 in bidentate ON pattern through deprotonated phenolic-O and the azomethine-N. Density functional theory (DFT) and MOE-docking approaches are used to evaluate the molecular parameters and the binding propensity of the synthesized ligands and their complexes with 3s7s protein and to signify their inhibition strength. Besides, the anticancer, antimicrobial and antifungal activities have been screened against number of tumor cells and human pathogen strains. These in vitro studies reveal that Schiff base L4 and its complex, [Ni(L4-H)(OAc)(H2O)], have superior activities reflecting the importance of inserting bioactive pendant substituents such as thiazole ring and 3-fluorophenylazo to the pharmacophoric sulfonamide moiety. Moreover, some of the synthesized Ni (II) complexes display promising therapeutic effects as novel non-platinum antitumor agents after further preclinical investigations.